At Last, Merck Is Diving Into Coronavirus Vaccine and Antiviral Development
Another giant pharmaceutical company has thrown its hat into the SARS-CoV-2 vaccine development ring: Merck (NYSE: MRK), which has up until now been quiet on the pandemic front. Meanwhile, its big pharma peers including GlaxoSmithKline (NYSE: GSK), AstraZeneca (NYSE: AZN), and Pfizer (NYSE: PFE) have signed numerous deals and reported significant progress on various vaccine programs.
Merck may have been slow to join the fight, but now, it's making up for lost time by acquiring one vaccine developer and initiating collaborations with two other organizations working on COVID-19 solutions.
Image source: Getty Images.
Source Fool.com
